Discussing the Evolution of Liquid Biopsies in Lung and Other Cancers
Benjamin P. Levy, MD, discusses the evolution of liquid biopsies in all solid tumors, especially in non–small cell lung cancer (NSCLC) where they are used routinely.
Benjamin P. Levy, MD, an assistant professor of oncology and the clinical director of Medical Oncology at Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the evolution of liquid biopsies in all solid tumors, especially in nonsmall cell lung cancer (NSCLC) where they are used routinely.
Historically, Levy says liquid biopsies were initially used to detect resistance to EGFR targeted therapies, but more recently, 2 data sets demonstrated their utility in addition to tissue biopsies in patients with advanced NSCLC. In breast cancer and gastrointestinal (GI) malignancies, some utility for liquid biopsies has been demonstrated recently, but it has not been as ironed out as it has been in lung cancer.
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
